Search research articles
Contact Us
Filters
Showing results (551-560 of 575) with videos related to
Page
of 58
Sort By:
Journal for Immunotherapy of Cancer
|
August 25, 2021
Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)
Natasha B Leighl, Mary W Redman, Naiyer Rizvi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2020
Phase IB Study of Osimertinib in Combination with Navitoclax in <i>EGFR</i>-mutant NSCLC Following Resistance to Initial <i>EGFR</i> Therapy (ETCTN 9903)
Erin M Bertino, Ryan D Gentzler, Sarah Clifford, et al.
JAMA Oncology
|
July 15, 2021
Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial
Scott N Gettinger, Mary W Redman, Lyudmila Bazhenova, et al.
Journal of the National Cancer Institute
|
July 28, 2019
Sex-Based Disparities Among Cancer Clinical Trial Participants
Ethan B Ludmir, C David Fuller, Shalini Moningi, et al.
Journal of Geriatric Oncology
|
November 13, 2019
Decreasing incidence of upper age restriction enrollment criteria among cancer clinical trials
Ethan B Ludmir, Ishwaria M Subbiah, Walker Mainwaring, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 26, 2026
PROSPECT-LUNG: A National Clinical Trials Network Trial Advancing Pragmatic Innovation in Cancer Clinical Trials
Allison Booth, Shauna Hillman, Kristina Laumann, et al.
JCO Precision Oncology
|
October 30, 2025
Multi-Institution Analysis of Tarlatamab for the Treatment of <i>EGFR</i>-Mutant Transformed Small Cell Lung Cancer
Alissa J Cooper, Benjamin Herzberg, Mitchell Parma, et al.
British Journal of Cancer
|
September 4, 2021
NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types
Christian Rolfo, Alexander Drilon, David Hong, et al.
Regulatory Toxicology and Pharmacology : RTP
|
May 11, 2026
Retrospective Evaluation of the OECD Adopted In Vitro Skin Irritation/Corrosion Tests for Agrochemical Formulations
Amber B Daniel, Andreia Oliveira Latorre, Arthur Grivel, et al.
Nature Communications
|
October 17, 2025
Author Correction: Cross-species comparison reveals therapeutic vulnerabilities halting glioblastoma progression
Leo Carl Foerster, Oguzhan Kaya, Valentin Wüst, et al.
Page
of 58
Search research articles
Search
Showing results (551-560 of 575) with videos related to
Sort By:
Page
of 58
Journal for Immunotherapy of Cancer
|
August 25, 2021
Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)
Natasha B Leighl, Mary W Redman, Naiyer Rizvi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2020
Phase IB Study of Osimertinib in Combination with Navitoclax in <i>EGFR</i>-mutant NSCLC Following Resistance to Initial <i>EGFR</i> Therapy (ETCTN 9903)
Erin M Bertino, Ryan D Gentzler, Sarah Clifford, et al.
JAMA Oncology
|
July 15, 2021
Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial
Scott N Gettinger, Mary W Redman, Lyudmila Bazhenova, et al.
Journal of the National Cancer Institute
|
July 28, 2019
Sex-Based Disparities Among Cancer Clinical Trial Participants
Ethan B Ludmir, C David Fuller, Shalini Moningi, et al.
Journal of Geriatric Oncology
|
November 13, 2019
Decreasing incidence of upper age restriction enrollment criteria among cancer clinical trials
Ethan B Ludmir, Ishwaria M Subbiah, Walker Mainwaring, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 26, 2026
PROSPECT-LUNG: A National Clinical Trials Network Trial Advancing Pragmatic Innovation in Cancer Clinical Trials
Allison Booth, Shauna Hillman, Kristina Laumann, et al.
JCO Precision Oncology
|
October 30, 2025
Multi-Institution Analysis of Tarlatamab for the Treatment of <i>EGFR</i>-Mutant Transformed Small Cell Lung Cancer
Alissa J Cooper, Benjamin Herzberg, Mitchell Parma, et al.
British Journal of Cancer
|
September 4, 2021
NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types
Christian Rolfo, Alexander Drilon, David Hong, et al.
Regulatory Toxicology and Pharmacology : RTP
|
May 11, 2026
Retrospective Evaluation of the OECD Adopted In Vitro Skin Irritation/Corrosion Tests for Agrochemical Formulations
Amber B Daniel, Andreia Oliveira Latorre, Arthur Grivel, et al.
Nature Communications
|
October 17, 2025
Author Correction: Cross-species comparison reveals therapeutic vulnerabilities halting glioblastoma progression
Leo Carl Foerster, Oguzhan Kaya, Valentin Wüst, et al.
Page
of 58